
The geographic atrophy treatment was approved by the FDA in the US earlier this month.

Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.

An area that attracts tourists and Christian pilgrims from around the world, has been found to contain microsporidium, which can cause corneal infections.

According to the company, the MAA submission is based on data from the GATHER1 and GATHER2 Phase III clinical trials.

Treatment requires a systematic, multifaceted approach to improve outcomes.

Without treatment, severe visual impairment can occur; the first-line treatment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

Without treatment, severe visual impairment can occur; the first-line treatment for these cases is anti-vascular endothelial growth factor therapy (VEGF).


The 2023 SOE meeting featured symposia, awards and a spotlight on young ophthalmologists

Researchers combine blue reflectance, red/green 200° ultrawidefield images

APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

Physicians ask the right questions and take an aggressive approach to treatment.

To heighten precision, use total keratometry, not imaginary numbers


It is important that patients know cataract surgery is a routine, safe procedure that will improve their quality of life.

Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.

A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.

A team of researchers from the Netherlands Institute for Neuroscience, one of the causes is the spontaneous back-and-forth movement of the eye is pendular nystagmus. The researchers have demonstrated that the nucleus of the optic tract might be the source of the problem.


Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

Staging AMD accurately and identifying clinical features that are linked with disease progression are key.

The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.

Eye symptoms such as dry, itchy, red, painful, watery, and gritty eyes can happen before the smoke is even noticeable.

Theodore Leng, MD, sat down with David Hutton of Ophthalmology Times®, to discuss his ASRS presentation on how the real-world use of faricimab.

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of August 6, 2023.